These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38373689)

  • 1. CD24 negativity reprograms mitochondrial metabolism to PPARα and NF-κB-driven fatty acid β-oxidation in triple-negative breast cancer.
    Murthy D; Dutta D; Attri KS; Samanta T; Yang S; Jung KH; Latario SG; Putluri V; Huang S; Putluri N; Park JH; Kaipparettu BA
    Cancer Lett; 2024 Apr; 587():216724. PubMed ID: 38373689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the Novel Role of CD24 as an Oncogenesis Regulator and Therapeutic Target for Triple-Negative Breast Cancer.
    Chan SH; Tsai KW; Chiu SY; Kuo WH; Chen HY; Jiang SS; Chang KJ; Hung WC; Wang LH
    Mol Cancer Ther; 2019 Jan; 18(1):147-161. PubMed ID: 30381446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.
    Sulaiman A; McGarry S; Li L; Jia D; Ooi S; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Gadde S; Li X; Wang L
    Mol Oncol; 2018 Apr; 12(4):423-440. PubMed ID: 29316250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of human breast cancer CD44
    Qiao X; Zhang Y; Sun L; Ma Q; Yang J; Ai L; Xue J; Chen G; Zhang H; Ji C; Gu X; Lei H; Yang Y; Liu C
    Elife; 2021 Jul; 10():. PubMed ID: 34318746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer.
    Ahn S; Park JH; Grimm SL; Piyarathna DWB; Samanta T; Putluri V; Mezquita D; Fuqua SAW; Putluri N; Coarfa C; Kaipparettu BA
    Cancer Res; 2024 Jan; 84(2):291-304. PubMed ID: 37906431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
    Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
    Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
    Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
    J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.
    Sinha A; Paul BT; Sullivan LM; Sims H; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    Oncotarget; 2017 Feb; 8(6):10114-10135. PubMed ID: 28052035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer.
    Park JH; Vithayathil S; Kumar S; Sung PL; Dobrolecki LE; Putluri V; Bhat VB; Bhowmik SK; Gupta V; Arora K; Wu D; Tsouko E; Zhang Y; Maity S; Donti TR; Graham BH; Frigo DE; Coarfa C; Yotnda P; Putluri N; Sreekumar A; Lewis MT; Creighton CJ; Wong LC; Kaipparettu BA
    Cell Rep; 2016 Mar; 14(9):2154-2165. PubMed ID: 26923594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metalloprotease-dependent activation of EGFR modulates CD44
    Wise R; Zolkiewska A
    Breast Cancer Res Treat; 2017 Nov; 166(2):421-433. PubMed ID: 28791489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT3 as a promising chemoresistance biomarker associated with the CD44
    Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
    Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Sonic Hedgehog Signaling Pathway by Thiazole Antibiotic Thiostrepton Attenuates the CD44+/CD24-Stem-Like Population and Sphere-Forming Capacity in Triple-Negative Breast Cancer.
    Yang N; Zhou TC; Lei XX; Wang C; Yan M; Wang ZF; Liu W; Wang J; Ming KH; Wang BC; Xu BL; Liu Q
    Cell Physiol Biochem; 2016; 38(3):1157-70. PubMed ID: 26963129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased expression of autophagy protein LC3 and stemness (CD44+/CD24-/low) indicate poor prognosis in triple-negative breast cancer.
    Chang SJ; Ou-Yang F; Tu HP; Lin CH; Huang SH; Kostoro J; Hou MF; Chai CY; Kwan AL
    Hum Pathol; 2016 Feb; 48():48-55. PubMed ID: 26772398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway.
    Chen X; Iliopoulos D; Zhang Q; Tang Q; Greenblatt MB; Hatziapostolou M; Lim E; Tam WL; Ni M; Chen Y; Mai J; Shen H; Hu DZ; Adoro S; Hu B; Song M; Tan C; Landis MD; Ferrari M; Shin SJ; Brown M; Chang JC; Liu XS; Glimcher LH
    Nature; 2014 Apr; 508(7494):103-107. PubMed ID: 24670641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC).
    Ma F; Li H; Wang H; Shi X; Fan Y; Ding X; Lin C; Zhan Q; Qian H; Xu B
    Cancer Lett; 2014 Oct; 353(2):153-9. PubMed ID: 25130168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer.
    Deng X; Apple S; Zhao H; Song J; Lee M; Luo W; Wu X; Chung D; Pietras RJ; Chang HR
    Oncotarget; 2017 Jun; 8(24):38294-38308. PubMed ID: 28418843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation.
    Wright HJ; Hou J; Xu B; Cortez M; Potma EO; Tromberg BJ; Razorenova OV
    Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6556-E6565. PubMed ID: 28739932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
    Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
    Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer.
    Yang P; Yu F; Yao Z; Ding X; Xu H; Zhang J
    Cancer Immunol Immunother; 2023 Oct; 72(10):3191-3202. PubMed ID: 37418008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.
    Azzam DJ; Zhao D; Sun J; Minn AJ; Ranganathan P; Drews-Elger K; Han X; Picon-Ruiz M; Gilbert CA; Wander SA; Capobianco AJ; El-Ashry D; Slingerland JM
    EMBO Mol Med; 2013 Oct; 5(10):1502-22. PubMed ID: 23982961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.